Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary structure-based drug design platform has enabled us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, ADHD, diabetes, schizophrenia, migraine, and other diseases. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including Cubist, MorphoSys, AstraZeneca and Takeda.

Latest News

Jan 23, 2015

Heptares Scientists To Receive The Malcolm Campbell Memorial Prize For 2015 In Recognition Of Their Outstanding Contribution To GPCR Drug...

Jan 22, 2015

Heptares Technology Enables Breakthrough In Drug Discovery Collaboration With AstraZeneca


Feb 1-6, 2015
Molecular Pharmacology Gordon Conference
Ventura, USA
Presenting: Fiona Marshall

Feb 8-13, 2015
Keystone meeting on Antibodies as Drugs: Immunological Scaffolds as Therapeutics
Banff, Canada
Presenting: Cath Hutchings

© 2012-2015 Heptares Therapeutics